Biogenerics Get A Low Score From CBO, But Is BIO Actually The Loser?
Executive Summary
The reaction of stakeholders to the Congressional Budget Office's score of potential savings from follow-on biologics illustrates the challenges for the various players as debate on legislation continuesYou may also be interested in...
Follow-On Biologics' Bumpy Pathway: Was The CBO Savings Score Too High?
Follow-On Biologics' Bumpy Pathway: Was The CBO Savings Score Too High?
Follow-on Biologics Savings Lower In Administration Budget Proposal
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: